Business
INVO Bioscience Announces Appointment of Barbara Ryan and Matthew Szot to the Board of Directors
INVO's Board strengthened with independent directors as we enter a new growth trajectory for the Company SARASOTA, Fla., Sept. 16, 2020 /PRNewswire/ -- INVO
About this update from Invo Fertility, Inc.
[{"type":"text","content":"INVO's Board strengthened with independent directors as we enter a new growth trajectory for the Company\n\n\nSARASOTA, Fla., Sept. 16, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced the appointment of two seasoned executives, Barbara Ryan and Matthew Szot, to its board of directors, effective immediately. To make way for their appointments, Kathleen Karloff and Michael Campbell have both agreed to voluntarily step down from their board positions to assist the company in achieving an independent board majority. Mr. Campbell will remain as Chief Operating Officer and Vice President of Business Development, while Ms. Karloff intends to continue to advise the board and assist the operating team on a go forward basis.\n\"We are pleased to add two highly experienced independent directors to our Board, which improves the governance of our Company,\" said Steve Shum, Chief Executive Office of INVO Bioscience. \"I would like to personally welcome Barbara and Matt to the board. Barbara has extensive capital markets experience as a highly regarded Wall Street analyst and later as a consultant to a wide variety of healthcare companies. Matt is a seasoned financial executive with strong board governance and audit committee experience. I believe both will be valuable assets to the Company as we advance our mission to expand fertility treatment and access to patient care across the globe through our revolutionary INVOcell device, an affordable, scalable and effective solution.\"\nMr. Shum concluded, \"INVO Bioscience would not be in the unique position to significantly expand the fertility industry through its revolutionary INVOcell solution if not for the hard work and dedication of Katie Karloff. I would like to thank Katie for her long-term commitment to the Company and look forward to her continued guidance in an advisory capacity.\"\nIn connection with the appointments of Ms. Ryan and Mr. Szot, along with existing independent board member, Trent Davis, Independent directors now comprise the majority of our Board and the company has established all of the key required board committees, including Audit, Compensation, and Nomi...